ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.